预约演示
Atom Bioscience Marks Gout Awareness Day by Urging Increased Patient Education on Debilitating Effects of the Chronic Disease
2023-05-22
JIANGSU, China--(BUSINESS WIRE)--Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for metabolic and inflammatory diseases, such as gout, is calling for increased understanding of gout to help mark Gout Awareness Day, May 22, 2023. The company released a video, https://atombp.us/ highlighting causes of the disease, how it can lead to more serious conditions and the company’s efforts to develop a new treatment.
Dr. William Shi, Founder and CEO of Atom Bioscience stated, “In treating gout, we have to do more than ease the painful symptoms of gout flare-ups. We must target the underlying cause by reducing excessive uric acid levels in the blood, which not only lead to gout, but also serious conditions such as permanent joint damage, heart attacks and kidney disease. The patient needs to bring their serum uric acid down to 5mg/dL.”
More than 55 million people suffer from gout worldwide, and its prevalence is increasing yearly. Over 9.3 million people in the U.S suffer from the disease, and the annual cost to the U.S. health care system is tens of billions of dollars.
Gout is one of the most common types of inflammatory arthritis. It is caused by a long-term condition known as hyperuricemia, defined as excessive uric acid levels in the blood (> 7 mg/dL). The build-up of uric acid is caused by genetic mutations in uric acid transport mechanisms in the kidney and bowel.
When the transporters don’t function, uric acid is not properly excreted from the body. Excessive uric acid can lead to the formation of crystals in joints and soft tissues, causing debilitating inflammation and the development of urate kidney stones.
About Atom Bioscience
Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co. Ltd.) is a fast-growing innovative drug company, focused on development of best in class small molecule therapeutics for treatment of inflammatory and metabolic diseases. The company’s lead product, ABP-671, is in clinical development for treatment of chronic gout. For more information please visit: https://atombp.us/.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。